Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 4.88 -0.07 (-1.41%)
price chart
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks.
Arena Pharmaceuticals Inc.: Arena Pharmaceuticals Enters into Marketing and ...
SAN DIEGO, July 21, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ� ...
Related articles »  
Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today
NEW YORK (TheStreet) -- Arena Pharmaceuticals (ARNA_) shares are plummeting, down -8.1% to $5.37, on Monday after CEO Jack Lief sold 223,525 shares of the company at an average price $5.85 for a total transaction of $1,307,621.25, according to an ...
Arena Stock Takes A Tumble � CEO Sells Shares, Investor Confidence Falls  Bidness Etc
Arena chief's stock sale invites criticism (ARNA)  Seeking Alpha
Related articles »  
Investors Alert: CTI BioPharma Corp. (NASDAQ:CTIC), Arena Pharmaceuticals ...
(NASDAQ:CTIC), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Geron Corporation (NASDAQ:GERN). CTI BioPharma Corp. (NASDAQ:CTIC)'s shares jumped 6.28% to $2.75.
Related articles »  
Arena Gives Pipeline Exposure - Is The Company Partner Shopping? (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators" by the United States Patent and Trademark Office, for APD371, an agonist of the cannabinoid receptor 2 ...
Arena Pharmaceuticals Pain Candidate Gets New U.S. Patent
Morning Alert - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Achillion ...  Techsonian (press release)
Related articles »  
News Recap-Newcastle Investment Corp. (NYSE:NCT),Arena Pharmaceuticals ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ� (lorcaserin HCl) with Teva Pharmaceutical Industries ...
Related articles »  
Big Movers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc ...
VIVUS, Inc. (NASDAQ:VVUS) on 12 June announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis. On last ...
Morning Alert : VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ ...  Crazy Joys
Related articles »  
Movers to Watch - Arena Pharmaceuticals, Inc. (ARNA),Celgene Corporation ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) gaining 2.91% and closed at $4.95 on a traded volume of 5.21 million shares, in comparison to 5.75 million shares of average trading volume.
Hot Alert � Arena Pharmaceuticals (NASDAQ:ARNA), International Business ...
On July 08, 2014, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock lost 9.42% of their value after Jack Lief, the CEO of the company, sold approximately 40% of his total stake in the company.
Arena Stock Rises With Expected Jump In Belviq Sales (ARNA)
I have also been looking at the cash side of Arena more closely to assess the time frame that the company may need to bring in more cash.
Related articles »